Literature DB >> 15159345

Recognizing neuroleptic malignant syndrome.

Patricia I Rosebush, Sarah Garside, Michael F Mazurek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15159345      PMCID： PMC408484          DOI： 10.1503/cmaj.1031692

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Bromocriptine and neuroleptic malignant syndrome.

Authors:  P I Rosebush; M F Mazurek
Journal:  J Clin Psychiatry       Date:  1991-01       Impact factor: 4.384

2.  A prospective analysis of 24 episodes of neuroleptic malignant syndrome.

Authors:  P Rosebush; T Stewart
Journal:  Am J Psychiatry       Date:  1989-06       Impact factor: 18.112

3.  Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients.

Authors:  P I Rosebush; T D Stewart; A J Gelenberg
Journal:  J Clin Psychiatry       Date:  1989-08       Impact factor: 4.384

4.  The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?

Authors:  P I Rosebush; T Stewart; M F Mazurek
Journal:  Br J Psychiatry       Date:  1991-11       Impact factor: 9.319

5.  Neuroleptic malignant syndrome: case report and discussion.

Authors:  Geethan J Chandran; John R Mikler; David L Keegan
Journal:  CMAJ       Date:  2003-09-02       Impact factor: 8.262
  5 in total
  1 in total

Review 1.  Managing an effective treatment for neuroleptic malignant syndrome.

Authors:  Udo Reulbach; Carmen Dütsch; Teresa Biermann; Wolfgang Sperling; Norbert Thuerauf; Johannes Kornhuber; Stefan Bleich
Journal:  Crit Care       Date:  2007       Impact factor: 9.097
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.